Why Preventing Cancer Is Not the Priority in Drug Development

The profits lie in treating later-stage cancers; a study shows it’s because of the incentives in the interplay between the patent system and the F.D.A. approval process. By Austin Frakt.
Read more: http://ift.tt/1PALbNs